Progress on the Function and Application of Thymosin β4
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and therapeutic literature without systematic methodology
OpenAlex W4200444708 · doi:10.3389/fendo.2021.767785
What was done
This is a narrative review summarizing the physiological functions, mechanisms of action, and translational applications of the peptide Thymosin β4 (Tβ4) across animal models and clinical trials.
What was found
The abstract provides purely qualitative summaries: Tβ4 is described as increasing angiogenesis and cell proliferation while inhibiting apoptosis and inflammation. It lists potential indications spanning myocardial infarction, myocardial ischemia-reperfusion injury, xerophthalmia, liver and renal fibrosis, ulcerative colitis, colon cancer, and skin trauma. No quantitative metrics, effect sizes, or trial numbers are reported in the abstract.
Why it matters
It aggregates mechanistic and therapeutic concepts surrounding Thymosin β4, highlighting its potential utility in tissue repair, cardioprotection, and anti-inflammatory therapy.
Limits
The abstract provides no quantitative data, statistical synthesis, or explicit literature search criteria. As an unstructured review, it mixes preliminary animal research with human clinical studies without reporting sample sizes, comparative efficacy, or adverse effect profiles.
Cited by
- supports Allan Goldstein's laboratory isolated thymosin fraction 5 and identified thymosin alpha-1 and thymosin beta-4 from thymic tissue.